Upgrade to SI Premium - Free Trial

BofA Takes Numbers Down On Boston Scientific (BSX) After Negative FDA Letter On Paclitaxel

March 18, 2019 8:55 AM
BofA/Merrill Lynch analyst Bob Hopkins reiterated a Buy rating and $45.00 price target on Boston Scientific (NYSE: BSX) but took ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change